Autologous HB-adMSCs not checked
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Hope Biosciences autologous adipose-derived mesenchymal stem cells”In the company’s words, NCT05951777 on ClinicalTrials.gov
- Main trialPhase 2
- “This protocol is part of a clinical study to evaluate efficacy and safety of multiple intravenous administrations of HB-adMSCs for the treatment of Multiple Sclerosis.”In the company’s words, NCT06800404 on ClinicalTrials.gov
Other drugs for Relapsing Remitting Multiple Sclerosis (RRMS)
- IMU-838Immunic AG · Phase 3
- CT-P53Celltrion · Phase 3
- ABP 692Amgen · Phase 3
- Peginterferon beta-1aBiogen · Phase 3
- BCD-281Biocad · Phase 3
- OcrelizumabRoche · Phase 3
Coming up2
- Jan 2027Phase 2 trial completes · ClinicalTrials.gov
- Dec 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | Jan 2027 | "HB-adMSCs for the Treatment of Patients With Multiple Sclerosis" | |
| Phase 2Recruiting | Dec 2027 | Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026